Meet Acumetis at ISPOR Europe 2026!

November 8 – 11, 2026 | Vienna, Austria

Visit us at booth #827

The demands on evidence generation, value demonstration, and market access planning have never been greater. As Joint Clinical Assessments (JCA) become a reality across Europe and payer expectations continue to evolve, life sciences organisations are under increasing pressure to generate the right evidence, answer the right questions, and demonstrate value with confidence.

At Acumetis, we help teams connect evidence, strategy, and decision-making across the product lifecycle, transforming complex evidence into actionable insights that support reimbursement, access, and launch success. Meet our Global Value & Access team at ISPOR Europe 2026 to discuss the challenges shaping market access and evidence strategy today.

Prepared for JCA? Let’s test that.

The shift to European HTA collaboration is raising the bar for evidence planning. Organisations need confidence that their evidence strategies will stand up to increasingly rigorous assessment requirements.

We help teams evaluate:

• JCA readiness and evidence strategy alignment
• PICO development and optimisation
• Evidence gap identification
• Comparator and endpoint strategy
• Cross-functional evidence planning

Built to move faster? Let’s find out.

We work with organisations to connect evidence generation, HEOR, Medical Affairs, Market Access, and Commercial Strategy earlier in development, helping teams make more informed decisions and reduce downstream challenges.

Speak with us about:

• Early evidence planning
• Integrated evidence generation strategies
• Real-world evidence planning
• Global evidence frameworks
• Evidence generation for future access success

Ready for launch? Let’s prove it.

Successful launches require more than strong clinical data. They require compelling evidence packages, clear value narratives, and strategies built around the needs of HTA bodies, payers, clinicians, and patients.

We’ll be discussing:

• Value demonstration strategies
• Health economics and outcomes research (HEOR)
• Pricing and reimbursement planning
• Global market access strategy
• Stakeholder-focused value communications
• Patient access optimisation
• Key Topics We’re Discussing at ISPOR Europe 2026

Whether you’re preparing for a forthcoming HTA submission, refining your evidence strategy, strengthening your value narrative, or planning for launch, we’d welcome the opportunity to discuss your priorities.

Visit the Acumetis team at Booth 827 throughout ISPOR Europe 2026 and learn how we help life sciences organisations create the critical connections between evidence, value, and access.

Schedule a meeting with our Global Value & Access team during ISPOR Europe and explore:

• How prepared your organisation is for JCA
• Whether your evidence strategy answers future HTA requirements
• Opportunities to strengthen value demonstration
• Gaps that could impact access or reimbursement outcomes
• Ways to align evidence, access, and commercial objectives earlier
• Leave with practical perspectives on how to build stronger evidence strategies, accelerate decision-making, and improve launch preparedness.

Where to find us

You’ll find the Acumetis team at Booth 827 throughout the conference. Stop by to discuss your current priorities in evidence generation, value demonstration, HEOR, HTA, pricing, reimbursement, and patient access – or simply to learn more about how we support life sciences organizations in turning complex evidence into effective value and access strategies.

Who You’ll Meet

Esther Nzenza – Senior Partner, Global Value and Access Practice Lead

Esther Nzenza brings more than 23 years of pharmaceutical and biotechnology experience across market access, HEOR, and commercial leadership roles at national, regional, and global levels. Following the acquisition of Decisive Consulting, the company she founded in 2020, by Acumetis in 2025, she now leads the firm’s global Value & Access practice. Recognised as a 2024 Times and LDC Top 50 “One to Watch” business leader, Esther is known for solving complex market access challenges, driving organisational excellence, and uncovering new opportunities through innovative thinking.

Chris Crimes-Crompton – Partner, Global Value and Access

Chris Grimes-Crompton brings more than 30 years of experience across pharmaceuticals, biotechnology, and medical technology. He specialises in helping organisations demonstrate asset value, shape evidence and market access strategies, and navigate the path from development through to successful commercialisation. An experienced commercial leader, Chris has supported numerous go-to-market and capability-building initiatives, spanning pricing, market access, indication prioritisation, early access, and international launch strategy.

Tammy Wynne – Principal, Global Value and Access

Tammy Wynne is a value communication, market access, and HEOR specialist with more than 20 years of experience supporting global, regional, and country-level pharmaceutical and biotechnology teams. She has led a wide range of evidence generation and access strategy projects, with particular expertise in rare diseases, alongside extensive experience in neurology and oncology. Tammy is recognised for translating complex clinical, economic, and commercial evidence into compelling value narratives that support HTA submissions, reimbursement strategies, and successful market access outcomes.

Sabine Gaugris – Principal, Global Value and Access

Sabine Gaugris is a HEOR and market access leader with extensive experience across the pharmaceutical industry and consulting, providing strategic evidence generation, HTA, and value demonstration support across a broad range of therapeutic areas. She has led successful HTA submissions, developed global value dossiers and economic models, and directed outcomes research programmes including network meta-analyses, survival analyses, and real-world evidence studies. Drawing on senior roles at AbbVie, Janssen, and Merck, Sabine helps organisations translate robust evidence into compelling value strategies that support payer decision-making and patient access.

Benjamin Farrar – Director, Global Value and Access

Ben is a market access and HTA specialist with expertise across UK and EU health technology assessment, underpinned by a background in statistics and systematic literature reviews. He has led major Joint Clinical Assessment (JCA) projects in consultancy and has contributed to the clinical and statistical evaluation of NICE submissions as a member of an External Assessment Group (EAG). Ben has experience across a range of therapeutic areas, particularly oncology and rare diseases, with recent work spanning cystic fibrosis, multiple myeloma, and pancreatic cancer.

Katerina Papadimitropoulou – Director, Global Value and Access

Katerina Papadimitropoulou is a HEOR and biostatistics specialist with more than a decade of experience spanning consulting and industry, supporting evidence generation, health technology assessment, and value demonstration initiatives. She brings deep expertise in evidence synthesis methodologies, including network meta-analysis, indirect treatment comparisons, and survival analysis, alongside a growing focus on applying data science tools to enhance statistical innovation and decision-making. Known for her analytical rigour and collaborative approach, Katerina helps organisations address complex methodological challenges and translate data into robust evidence strategies that support market access and payer decision-making.

Caroline Hopkinson (Barwood) – Associate Director, Global Value and Access

Caroline Barwood has 8+ years of experience leading HTA submissions and market access strategy across the UK, Europe, Canada, and Australia. She brings broad HEOR expertise spanning cost-effectiveness and budget impact modelling, advanced statistical analysis, evidence synthesis, and the application of innovative approaches, including AI-assisted systematic literature reviews. Caroline has published across oncology, cardiology, and ophthalmology, with extensive experience in rare diseases, helping organisations develop robust evidence strategies that support payer decision-making and successful market access.

Lawrence Murphy – Director, Global Business Development

Lawrence Murphy holds 10+ years of experience across HEOR, market access, and life sciences commercialisation, supporting pharmaceutical, biotechnology, and medical technology organisations worldwide. He works closely with clients to navigate complex commercialisation challenges, connecting strategic, evidence, and access capabilities to help bring innovative therapies to patients more effectively. As part of Acumetis’ global commercial team, Lawrence helps organisations unlock value across Global Value & Access, Medical Affairs, Commercial Strategy, Launch Excellence, Insights & Analytics, and Patient Access, enabling more confident decision-making throughout the product lifecycle.

Milind Sood – Manager, Global Value and Access

Milind Sood leads strategic market access, evidence planning, and commercialisation projects for pharmaceutical and biotechnology clients. He brings expertise in EU HTA and Joint Clinical Assessments (JCA), value communication, primary research, and stakeholder engagement, helping organisations address complex access challenges and make informed decisions throughout the asset lifecycle. Alongside client delivery, Milind plays an active role in business development, capability building, and mentoring, combining a strong scientific foundation with a practical focus on translating evidence into successful market access strategies.

About Acumetis

Acumetis partners with life sciences organisations to solve complex strategic, scientific, and commercial challenges.

By bringing together expertise across Medical Affairs, Market Access, Commercial Strategy, Insights, and Patient Engagement, we help clients create the critical connections needed to generate evidence, demonstrate value, and improve patient access.

Our approach combines strategic thinking with practical execution, helping organisations move from evidence generation to meaningful impact.